Johnson & Johnson Profit Margin 2010-2024 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of March 31, 2024 is 45.26%.
Johnson & Johnson Annual Profit Margins
Johnson & Johnson Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $357.925B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $695.710B 115.85
Novo Nordisk (NVO) Denmark $566.147B 46.64
Merck (MRK) United States $321.695B 84.67
AbbVie (ABBV) United States $297.115B 15.10
AstraZeneca (AZN) United Kingdom $220.752B 19.56
Novartis AG (NVS) Switzerland $201.027B 14.25
Pfizer (PFE) United States $148.755B 14.35
Sanofi (SNY) $117.905B 10.62
Innoviva (INVA) United States $0.959B 6.77